Ignite Creation Date:
2025-12-24 @ 9:33 PM
Ignite Modification Date:
2026-01-01 @ 4:07 AM
Study NCT ID:
NCT07023432
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-06-17
First Post:
2025-06-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-12-03
Start Date Type:
ESTIMATED
Primary Completion Date:
2028-04-14
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-04-14
Completion Date Type:
ESTIMATED
First Submit Date:
2025-06-10
First Submit QC Date:
None
Study First Post Date:
2025-06-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-10
Last Update Post Date:
2025-06-17
Last Update Post Date Type:
ACTUAL